Patients often equate good doctors with thorough doctors, and thorough is interpreted as ordering every test available. Insurance plans now market “executive physicals” with full-body scans, comprehensive blood panels, and genetic screening as a premium experience. The intuition is appealing: more data must equal better health.
The evidence says otherwise. In medicine, more testing routinely produces worse outcomes — more false positives, more invasive follow-up procedures, more anxiety, and sometimes more harm than the original condition would have caused.
False positives compound quickly
Every test has a false positive rate. Run one test on a healthy person and the odds of an alarming wrong result are small. Run twenty and the math turns hostile. By statistical inevitability, multiple results will come back abnormal even though nothing is wrong. Each abnormal result triggers more imaging, more biopsies, more specialist visits. The US Preventive Services Task Force has repeatedly downgraded screening recommendations — including for prostate cancer, thyroid cancer, and routine vitamin D testing — specifically because population-wide screening produced more harm than benefit. The biopsies hurt people the cancers never would have.
Incidentalomas drive unnecessary procedures
Modern imaging is so sensitive it finds things on almost everyone — small thyroid nodules, kidney cysts, lung specks, adrenal lumps. Most are biologically irrelevant, the medical equivalent of background noise. Once they appear on a scan, however, the system has trouble ignoring them. Patients receive surveillance protocols, repeat imaging, and sometimes surgery for findings that would have stayed silent for life. A 2019 BMJ analysis estimated that overdiagnosis affects roughly 20 to 30 percent of certain cancer screenings, meaning real people are being treated — with real surgical and chemotherapeutic harm — for disease that wasn’t going to hurt them.
Targeted testing beats blanket testing
Good medicine is hypothesis-driven. A clinician listens, examines, weighs probability, and orders tests likely to change a decision. That sequence is unglamorous but powerful. Blanket testing skips the thinking and substitutes volume. Concierge clinics and direct-to-consumer health startups have built business models around this confusion, selling reassurance dressed as rigor. The tests are real; the value usually isn’t. The patients who do best in long-term studies are not those who get the most screenings. They are those whose primary care relationships allow targeted, age-appropriate testing aligned with actual risk factors and family history.
Bottom line
Testing is a tool, not a virtue. The right number of tests is the number that meaningfully changes what your doctor does next. Beyond that point, additional tests start subtracting from health rather than adding to it. Before agreeing to a panel, scan, or genetic screen, ask three questions: what decision will this result change, what’s the false positive rate, and what’s the follow-up if something looks abnormal. A doctor who can answer all three is offering medicine. A clinic that can’t is selling reassurance. Real care is targeted, contextual, and willing to leave some questions unanswered when answering them would do more harm than good.
Leave a Reply